Azacitidine Injection, Powder, Lyophilized, For Solution
Product Images NDC 71288-153

4 FDA label images from Meitheal Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Azacitidine (NDC 71288-153). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Aza06 0000 01)

Structural Formula (Aza06 0000 01)
Chemical structure diagram showing the molecular formula of Azacitidine, the active ingredient in the drug. The structure includes nitrogen-containing rings and hydroxyl groups, representing its chemical arrangement.*
FDA Label Image

Kaplan-meier Curve Of Time To Death From Any Cause (Aza06 0000 02)

Kaplan-meier Curve Of Time To Death From Any Cause (Aza06 0000 02)
A Kaplan-Meier survival curve comparing the proportion of patients surviving over time (months from randomization) between two groups labeled AZA and CCR. The graph shows survival probability on the Y-axis and time in months on the X-axis, with AZA having higher survival. Additional statistics include a log-rank p-value of 0.0001, hazard ratio with 95% confidence interval, and number of deaths for each group. The number of patients at risk at various time points is presented below the graph.*
FDA Label Image

Principal Display Panel – Azacitidine For Injection 100 mg Vial Label (Aza06 0000 03)

Principal Display Panel – Azacitidine For Injection 100 mg Vial Label (Aza06 0000 03)
Label of Azacitidine for Injection displaying 100 mg per vial strength as a lyophilized powder for solution, intended for subcutaneous and intravenous use. The label highlights it as a cytotoxic agent and single-dose vial, labeled by Meitheal Pharmaceuticals Inc. under the Novaplus brand with NDC 71288-153-95.*
FDA Label Image

Principal Display Panel – Azacitidine For Injection 100 mg Carton (Aza06 0000 04 V2)

Principal Display Panel – Azacitidine For Injection 100 mg Carton (Aza06 0000 04 V2)
Flat packaging label for Azacitidine injection, 100 mg per vial, presented as a lyophilized powder for solution. The label indicates it is for subcutaneous and intravenous use only, single-dose vial. The labeler is Meitheal Pharmaceuticals Inc., with the novaplus logo visible. Caution is noted for cytotoxic agent. Storage instructions and manufacturer details are included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.